Ultrasound Targeted Microbubble Destruction-mediated SOCS3 Attenuates Biological Characteristics and Epithelial-mesenchymal Transition (EMT) of Breast Cancer Stem Cells

Overview

Journal Bioengineered

Date 2022 Feb 3

PMID 35109743

Authors

Xiaojiang Tang

Na Hao

Yuhui Zhou

Yang Liu

Affiliations

Soon will be listed here.

Abstract

SOCS3 is low-expressed in breast cancer and may be a potential target. Ultrasound targeted microbubble destruction (UTMD) improved the efficiency of gene transfection. We explored the effects of UTMD-mediated transfection of SOCS3 on the biological characteristics and epithelial-mesenchymal transition (EMT) of breast cancer stem cells (BCSCs). The expression of SOCS3 in breast cancer (BC) and its association with prognosis were evaluated by GEPIA and The Cancer Genome Atlas (TCGA) websites. BCSCs were sorted by flow cytometry and immunomagnetic bead method, followed by sphere formation, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and xenograft assays to test their effects and . The levels of SOCS3, EMT- and STAT3 pathway-related genes were determined by RT-qPCR and Western blot, respectively. The effects of liposome and UTMD on BCSCs and mice were compared by the gain-of-function experiments. Low expression of SOCS3 was associated with poor prognosis of BC patients, and found in BC and BCSCs. BCSCs were successfully sorted, with high viability and tumorigenicity. UTMD increased the transfection rate of SOCS3. Moreover, UTMD- and liposome-mediated SOCS3 reduced cell viability, proliferation, migration and invasion, blocked cell cycle, inhibited sphere formation in BCSCs, and retarded tumor growth in mice. Mechanistically, overexpressed SOCS3 inhibited the expressions of EMT-related genes and the activation of STAT3 pathway in BCSCs and mice. The regulatory effects of UTMD-mediated SOCS3 on the above-mentioned biological characteristics were better than liposome-mediated SOCS3. UTMD-mediated SOCS3 has a better therapeutic effect in BC, providing new experimental evidence for the treatment of BC.

Citing Articles

Advances in Ultrasound-Targeted Microbubble Destruction (UTMD) for Breast Cancer Therapy.

Wu Y, Liu Y, Wu H, Tong M, Du L, Ren S Int J Nanomedicine. 2025; 20:1425-1442.

PMID: 39925678 PMC: 11804227. DOI: 10.2147/IJN.S504363.

Putative Dual Roles of Bone Morphogenetic Protein 8B (BMP8B) in Disease Progression of Gastric Cancer.

Sun Z, Cai S, Liu X, Jiang W, Ye L Cancer Diagn Progn. 2024; 4(5):567-578.

PMID: 39238632 PMC: 11372696. DOI: 10.21873/cdp.10365.

Ultrasound microbubble-mediated RNA interference targeting WNT1 inducible signaling pathway protein 1(WISP1) suppresses the proliferation and metastasis of breast cancer cells.

Fang F, Xu W, Zhang J, Gu J, Yang G Bioengineered. 2022; 13(4):11050-11060.

PMID: 35481425 PMC: 9208516. DOI: 10.1080/21655979.2022.2068738.

Luteolin impacts deoxyribonucleic acid repair by modulating the mitogen-activated protein kinase pathway in colorectal cancer.

Song Y, Yu J, Li L, Wang L, Dong L, Xi G Bioengineered. 2022; 13(4):10998-11011.

PMID: 35473479 PMC: 9161897. DOI: 10.1080/21655979.2022.2066926.

References

Anastasiadi Z, Lianos G, Ignatiadou E, Harissis H, Mitsis M . Breast cancer in young women: an overview. Updates Surg. 2017; 69(3):313-317. DOI: 10.1007/s13304-017-0424-1. View

Pedroso J, Ramos-Lobo A, Donato Jr J . SOCS3 as a future target to treat metabolic disorders. Hormones (Athens). 2018; 18(2):127-136. DOI: 10.1007/s42000-018-0078-5. View

Zhao R, Liang X, Zhao B, Chen M, Liu R, Sun S . Ultrasound assisted gene and photodynamic synergistic therapy with multifunctional FOXA1-siRNA loaded porphyrin microbubbles for enhancing therapeutic efficacy for breast cancer. Biomaterials. 2018; 173:58-70. DOI: 10.1016/j.biomaterials.2018.04.054. View

Ganz P, Goodwin P . Breast Cancer Survivorship: Where Are We Today?. Adv Exp Med Biol. 2015; 862:1-8. DOI: 10.1007/978-3-319-16366-6_1. View

Sun W, Shi Q, Zhang H, Yang K, Ke Y, Wang Y . Advances in the techniques and methodologies of cancer gene therapy. Discov Med. 2019; 27(146):45-55. View

Nassar D, Blanpain C . Cancer Stem Cells: Basic Concepts and Therapeutic Implications. Annu Rev Pathol. 2016; 11:47-76. DOI: 10.1146/annurev-pathol-012615-044438. View

Liao Y, Luo H, He Z, Kuang Y, Chen P, Zhang X . A Combination of UTMD-Mediated HIF-1 shRNA Transfection and TAE in the Treatment of Hepatic Cancer. Biomed Res Int. 2019; 2019:1937460. PMC: 6399560. DOI: 10.1155/2019/1937460. View

Ji Y, Han Z, Shao L, Zhao Y . Ultrasound-targeted microbubble destruction of calcium channel subunit α 1D siRNA inhibits breast cancer via G protein-coupled receptor 30. Oncol Rep. 2016; 36(4):1886-92. PMC: 5022872. DOI: 10.3892/or.2016.5031. View

Zou Y, Chen Y, Yao S, Deng G, Liu D, Yuan X . MiR-422a weakened breast cancer stem cells properties by targeting PLP2. Cancer Biol Ther. 2018; 19(5):436-444. PMC: 5915044. DOI: 10.1080/15384047.2018.1433497. View

10.

Barclay J, Anderson S, Waters M, Curlewis J . SOCS3 as a tumor suppressor in breast cancer cells, and its regulation by PRL. Int J Cancer. 2008; 124(8):1756-66. DOI: 10.1002/ijc.24172. View

11.

Xie G, Ji A, Yuan Q, Jin Z, Yuan Y, Ren C . Tumour-initiating capacity is independent of epithelial-mesenchymal transition status in breast cancer cell lines. Br J Cancer. 2014; 110(10):2514-23. PMC: 4021510. DOI: 10.1038/bjc.2014.153. View

12.

Inan S, Hayran M . Cell Signaling Pathways Related to Epithelial Mesenchymal Transition in Cancer Metastasis. Crit Rev Oncog. 2019; 24(1):47-54. DOI: 10.1615/CritRevOncog.2018029509. View

13.

Subramani R, Nandy S, Pedroza D, Lakshmanaswamy R . Role of Growth Hormone in Breast Cancer. Endocrinology. 2017; 158(6):1543-1555. DOI: 10.1210/en.2016-1928. View

14.

Jiang M, Zhang W, Zhang R, Liu P, Ye Y, Yu W . Cancer exosome-derived miR-9 and miR-181a promote the development of early-stage MDSCs via interfering with SOCS3 and PIAS3 respectively in breast cancer. Oncogene. 2020; 39(24):4681-4694. DOI: 10.1038/s41388-020-1322-4. View

15.

Wu J, Li R . Ultrasound-targeted microbubble destruction in gene therapy: A new tool to cure human diseases. Genes Dis. 2018; 4(2):64-74. PMC: 6136600. DOI: 10.1016/j.gendis.2016.08.001. View

16.

Liu K, Wu Z, Chu J, Yang L, Wang N . Promoter methylation and expression of SOCS3 affect the clinical outcome of pediatric acute lymphoblastic leukemia by JAK/STAT pathway. Biomed Pharmacother. 2019; 115:108913. DOI: 10.1016/j.biopha.2019.108913. View

17.

Groner B, von Manstein V . Jak Stat signaling and cancer: Opportunities, benefits and side effects of targeted inhibition. Mol Cell Endocrinol. 2017; 451:1-14. DOI: 10.1016/j.mce.2017.05.033. View

18.

Zhang W, Jiang M, Chen J, Zhang R, Ye Y, Liu P . SOCS3 Suppression Promoted the Recruitment of CD11bGr-1F4/80MHCII Early-Stage Myeloid-Derived Suppressor Cells and Accelerated Interleukin-6-Related Tumor Invasion Affecting Myeloid Differentiation in Breast Cancer. Front Immunol. 2018; 9:1699. PMC: 6064721. DOI: 10.3389/fimmu.2018.01699. View

19.

Speth J, Penke L, Bazzill J, Park K, Gil de Rubio R, Schneider D . Alveolar macrophage secretion of vesicular SOCS3 represents a platform for lung cancer therapeutics. JCI Insight. 2019; 4(20). PMC: 6824301. DOI: 10.1172/jci.insight.131340. View

20.

Al-Hajj M, Wicha M, Benito-Hernandez A, Morrison S, Clarke M . Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003; 100(7):3983-8. PMC: 153034. DOI: 10.1073/pnas.0530291100. View